Seo et al. [15] enrolled 48 patients with HER2-positive AGC treated with trastuzumab-containing first-line chemotherapy and investigated HER2 expression retrospectively, using IHC and/or FISH in tumor specimens at baseline and after PD to chemotherapy. Here, ERBB2 is linked to neoplasm.